Literature DB >> 198166

The role of dopaminergic depletion in the pathogenesis of Cushing's disease and the possible consequences for medical therapy.

S W Lamberts, H A Timmermans, F H De Jong, J C Birkenhager.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1977        PMID： 198166     DOI： 10.1111/j.1365-2265.1977.tb01314.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN： 0300-0664            Impact factor:   3.478


× No keyword cloud information.
  12 in total

1.  Treatment of pituitary macroadenomas secreting PRL, HGH or ACTH with long-acting bromocriptine.

Authors:  I Halperin; M D Rodriguez; C Cardenal; R Casamitjana; M J Martinez Osaba; V Lienas; E Vilardell
Journal:  J Endocrinol Invest       Date:  1987-06       Impact factor: 4.256

2.  Six year remission of ACTH-dependent Cushing's syndrome using bromocriptine.

Authors:  A B Atkinson; A L Kennedy; B Sheridan
Journal:  Postgrad Med J       Date:  1985-03       Impact factor: 2.401

Review 3.  The Treatment of Cushing's Disease.

Authors:  Rosario Pivonello; Monica De Leo; Alessia Cozzolino; Annamaria Colao
Journal:  Endocr Rev       Date:  2015-06-11       Impact factor: 19.871

4.  Cushing's disease and marked hyperprolactinemia in a patient with a pituitary macroadenoma: effectiveness of bromocriptine treatment.

Authors:  G Verde; P Loli; M E Berselli; M Tagliaferri; D Dallabonzana; G Oppizzi; A Liuzzi; P G Chiodini; G Luccarelli; S Lodrini
Journal:  J Endocrinol Invest       Date:  1984-02       Impact factor: 4.256

5.  Long term bromocriptine therapy in Cushing's disease.

Authors:  L P Kapcala; I M Jackson
Journal:  J Endocrinol Invest       Date:  1982 Mar-Apr       Impact factor: 4.256

6.  The use of cyproheptadine (peritol) as a drug blocking corticotropin secretion in the treatment of Itsenko-Cushing's disease.

Authors:  I V Komissarenko; A K Cheban; S I Rybakov; V I Slavnov; E V Luchitskii
Journal:  Neurosci Behav Physiol       Date:  1982 Nov-Dec

7.  Hypothalamic-pituitary function in Cushing's disease.

Authors:  D Le Roith; M S Shapiro; A Gutman; I M Spitz
Journal:  J Endocrinol Invest       Date:  1979 Oct-Dec       Impact factor: 4.256

8.  Lack of ACTH lowering effect of sodium valproate in patients with ACTH hypersecretion.

Authors:  P Loli; M E Berselli; F Frascatani; F Muratori; M Tagliaferri
Journal:  J Endocrinol Invest       Date:  1984-04       Impact factor: 4.256

9.  Effectiveness of cabergoline in monotherapy and combined with ketoconazole in the management of Cushing's disease.

Authors:  Lucio Vilar; Luciana A Naves; Monalisa F Azevedo; Maria Juliana Arruda; Carla M Arahata; Lidiane Moura E Silva; Rodrigo Agra; Lisete Pontes; Larissa Montenegro; José Luciano Albuquerque; Viviane Canadas
Journal:  Pituitary       Date:  2010-06       Impact factor: 4.107

10.  Cushing's disease: clinical and laboratory response to bromocriptine therapy.

Authors:  M O de Pinho; R C Antunes; M B Lima; C C Francalanci; S Franco
Journal:  J Endocrinol Invest       Date:  1984-12       Impact factor: 4.256
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.